urea has been researched along with Lymphoma, B-Cell, Marginal Zone in 3 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Lymphoma, B-Cell, Marginal Zone: Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Guevara, B | 1 |
| Cogdill, AG | 1 |
| Garza-González, E | 1 |
| Perez-Perez, GI | 1 |
| Maldonado-Garza, HJ | 1 |
| Bosques-Padilla, FJ | 1 |
| Zucca, E | 1 |
| Dreyling, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial[NCT04039412] | Phase 4 | 330 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 49 |
| (2) Hybrid Regimen | 58 |
| (3) Levofloxacin Quadruple Regimen | 44 |
Measuring the curative rate of each regimen by a fecal antigen test (NCT04039412)
Timeframe: 40-44 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 102 |
| (2) Hybrid Regimen | 101 |
| (3) Levofloxacin Quadruple Regimen | 91 |
Questionnaire to evaluate the compliance with each treatment regimen (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 109 |
| (2) Hybrid Regimen | 107 |
| (3) Levofloxacin Quadruple Regimen | 108 |
2 reviews available for urea and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Biopsy; Bismuth; Breath | 2020 |
A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication.
Topics: Anti-Bacterial Agents; Biopsy; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Helicobacte | 2014 |
1 other study available for urea and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; beta 2-Microglobulin; Biomarkers; Biopsy; Breath Test | 2010 |